









Markets
/
Stocks
/
nasdaq-lfcr
/

Lifecore Biomedical Inc

LFCR

7.930USD

+0.230+2.99%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

293.62MMarket Cap

LossP/E TTM



Lifecore Biomedical Inc

7.930

+0.230+2.99%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

76 / 175

Overall Ranking

205 / 4723

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

10.000

Target Price

+27.23%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 24.79% year-on-year.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD 44.36M.%!(EXTRA int=2)

Undervalued

The company’s latest PE is -6.04, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 27.35M shares, decreasing 9.34% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.61M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 7.27, which is lower than the Pharmaceuticals industry's average of 7.84. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 36.44M, representing a year-over-year decrease of 3.81%, while its net profit experienced a year-over-year decrease of 71.10%.

Score

Industry at a Glance

Previous score

7.27

Change



Financials

7.25

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.29

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.24

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.28

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.26

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -6.04, which is -65.83% below the recent high of -2.06 and 25.58% above the recent low of -4.50.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 76/175

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 7.50, which is lower than the Pharmaceuticals industry's average of 7.78. The average price target for Lifecore Biomedical Inc is 10.00, with a high of 10.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

7.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

10.000

Target Price

+29.87%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Lifecore Biomedical Inc

LFCR

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 7.11, which is higher than the Pharmaceuticals industry's average of 6.64. Sideways: Currently, the stock price is trading between the resistance level at 8.59 and the support level at 6.90, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.23

Change

-0.12

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.084

Buy

RSI(14)

56.889

Neutral

STOCH(KDJ)(9,3,3)

76.798

Buy

ATR(14)

0.422

High Vlolatility

CCI(14)

102.986

Buy

Williams %R

44.970

Buy

TRIX(12,20)

0.091

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

7.738

Buy

MA10

7.555

Buy

MA20

7.566

Buy

MA50

7.533

Buy

MA100

7.325

Buy

MA200

6.893

Buy

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 73.90%, representing a quarter-over-quarter decrease of 9.40%. The largest institutional shareholder is The Vanguard, holding a total of 1.61M shares, representing 4.35% of shares outstanding, with 5.17% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Wynnefield Capital, Inc.

4.70M

Legion Partners Asset Management, LLC

4.43M

Greenhaven Road Investment Management, L.P.

3.62M

325 Capital LLC

2.16M

+172.80%

Laughing Water Capital, LP

1.90M

+20.39%

David Capital Partners, LLC

1.80M

+8.94%

BlackRock Institutional Trust Company, N.A.

1.63M

+8.97%

The Vanguard Group, Inc.

Star Investors

1.55M

+1.04%

Geode Capital Management, L.L.C.

750.50K

+9.44%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 4.91, which is higher than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.63. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.